Loading…
Galectin Therapeutics Inc. is projected to rise to $4.84 by 2027, a +63% move from its current price of $2.97. GALT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.80 | $2.97 | $3.15 | -0.07% |
| Aug 4 | $2.73 | $2.97 | $3.22 | -0.15% |
| Aug 5 | $2.68 | $2.96 | $3.28 | -0.22% |
| Aug 6 | $2.63 | $2.96 | $3.33 | -0.30% |
| Aug 7 | $2.60 | $2.96 | $3.37 | -0.37% |
| Aug 8 | $2.56 | $2.96 | $3.41 | -0.44% |
| Aug 9 | $2.53 | $2.95 | $3.45 | -0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.53 | $2.95 | $3.45 | -0.52% |
| Week 2 | $2.36 | $2.94 | $3.66 | -1.03% |
| Week 3 | $2.24 | $2.92 | $3.82 | -1.54% |
| Week 4 | $2.14 | $2.91 | $3.96 | -2.05% |
| Week 5 | $2.05 | $2.89 | $4.09 | -2.55% |
| Week 6 | $1.97 | $2.88 | $4.20 | -3.06% |
| Week 7 | $1.90 | $2.86 | $4.31 | -3.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Galectin Therapeutics Inc. is a clinical stage biopharmaceutical company focused on drug development to create new therapies for fibrotic disease and cancer. Its lead product candidate belapectin (GR-MD-02), a galectin-3 inhibitor, is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. Galectin Therapeutics Inc. was formerly known as Pro-Pharmaceuticals, Inc.
and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc. (GALT) is a healthcare stock currently trading at $2.97 with a market cap of $195.59M, ranking at 3768. The shares belong to the Healthcare sector and reflect a current price that sits in a growth trajectory suggested by the long-range forecast.
For 2026 the forecast shows min $2.08, avg $2.97, max $4.30 with sentiment NEUTRAL and ROI 0. The path from 2027 onward is shown as bullish, with higher average prices and meaningful gains by 2030 and beyond. By 2030 the avg is $6.04, and by 2050 the avg is $32.26, with a forecast ROI of 103.3% in 2030 and 986.2% in 2050.
A major floor 60.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 79.8% above — a clean break opens room to run.
A major ceiling 110.2% above — clearing it would confirm fresh momentum.
Key GALT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GALT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.29 | Sell | $3.27 | Sell |
| MA 10 | $3.47 | Sell | $3.49 | Sell |
| MA 20 | $4.00 | Sell | $3.69 | Sell |
| MA 50 | $3.42 | Sell | $3.50 | Sell |
| MA 100 | $2.96 | Buy | $3.32 | Sell |
| MA 200 | $3.65 | Sell | $3.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.88 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -130.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -37.61 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | -0.56 | Sell |
| Ultimate (7,14,28) | 24.08 | Buy |
| Momentum (10) | -1.21 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.19 | Sell |
| ADX (14) | 21.62 | Sell |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 40. The SMA50 is $3.42 and the SMA200 is $3.65, with a key support at $2.80 and resistance at $5.34. The thirty-day range spans from $2.02 to $4.37, and annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.08 | $2.97 | $4.30 | 0% | Neutral | |
| $3.53 | $4.84 | $7.18 | +63% | Bullish | |
| $3.83 | $5.59 | $8.85 | +88% | Bullish | |
| $3.66 | $5.64 | $9.37 | +90% | Bullish | |
| $3.74 | $6.04 | $10.46 | +103% | Bullish | |
| $3.58 | $6.05 | $10.84 | +104% | Bullish | |
| $3.69 | $6.50 | $12.02 | +119% | Bullish | |
| $4.12 | $7.54 | $14.34 | +154% | Bullish | |
| $5.36 | $10.22 | $19.92 | +244% | Bullish | |
| $6.48 | $12.84 | $25.61 | +332% | Bullish | |
| $6.87 | $15.27 | $33.49 | +414% | Bullish | |
| $14.52 | $32.26 | $74.20 | +986% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.08 | $2.97 | $3.75 | +0.00% |
| September 2026 | $2.32 | $2.83 | $3.59 | -4.77% |
| October 2026 | $2.25 | $2.78 | $3.60 | -1.83% |
| November 2026 | $2.46 | $3.07 | $4.04 | +10.40% |
| December 2026 | $2.55 | $3.22 | $4.30 | +4.94% |
Click any year to see its month-by-month GALT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GALT could reach as high as $4.30, with a base case around $2.97 and support toward $2.08 — roughly 0% from $2.97. A consolidation phase looks the most probable path here.
Expect GALT to range from $3.53 to $7.18 through 2027. The $4.84 average target implies a +63% move from current prices. That is up +63% on the projected 2026 average. Momentum favours further upside here.
The GALT price prediction for 2028 points to an average of $5.59 (low $3.83, high $8.85) — a potential gain of +88% on today's $2.97. Buyers look set to stay in control over this stretch.
In 2029, GALT is projected to trade between $3.66 and $9.37, averaging $5.64 — a potential gain of +90% from today's $2.97. That is up +1% on the projected 2028 average. Momentum favours further upside here.
Galectin Therapeutics Inc.'s 2030 outlook centres on $6.04, within a $3.74 to $10.46 range. That is up +7% on the projected 2029 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GALT could reach as high as $10.84, with a base case around $6.05 and support toward $3.58 — roughly +104% from $2.97. Momentum favours further upside here.
Expect GALT to range from $3.69 to $12.02 through 2032. The $6.50 average target implies a +119% move from current prices. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The GALT price prediction for 2033 points to an average of $7.54 (low $4.12, high $14.34) — a potential gain of +154% on today's $2.97. Momentum favours further upside here.
In 2034, GALT is projected to trade between $5.36 and $19.92, averaging $10.22 — a potential gain of +244% from today's $2.97. That is up +36% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Galectin Therapeutics Inc.'s 2035 outlook centres on $12.84, within a $6.48 to $25.61 range. That is up +26% on the projected 2034 average. That marks a +332% change versus current levels. Momentum favours further upside here.
By 2040, GALT could reach as high as $33.49, with a base case around $15.27 and support toward $6.87 — roughly +414% from $2.97. Buyers look set to stay in control over this stretch.
Expect GALT to range from $14.52 to $74.20 through 2050. The $32.26 average target implies a +986% move from current prices. That is up +111% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GALT today (≈ 336.700337 GALT) could be worth
$10,862.31
+$9,862.31 (+986%) by 2050 · US Dollar
Based on the average projected GALT price of $32.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GALTwould be worth at today's price.
$1,000 invested in GALT on Jul 31, 2025 (≈ 274.725267 GALT) would be worth
$815.93
-$184.07 (-18.4%) today · 0.82× · US Dollar
Based on a GALT entry price of $3.64 vs. today's $2.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.47 | $855.91 | -14.4% |
| 1 month ago | $4.33 | $685.91 | -31.4% |
| 3 months ago | $2.27 | $1,308.37 | +30.8% |
| 6 months ago | $3 | $990 | -1.0% |
| 1 year ago | $3.64 | $815.93 | -18.4% |
| All time (5.0y) ago | $2.99 | $993.31 | -0.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GALT forecast.
Our base-case forecast reaches $5.90 around 2030.
Implied market cap at $5.90: $388.56M
The multi-year forecast shows a bullish path after 2026. In 2027 the average price is $4.84 (ROI 63) and in 2028 it is $5.59 (ROI 88.3), followed by 2029 at $5.64 (ROI 89.8) and 2030 at $6.04 (ROI 103.3). The outlook then extends to 2031 with $6.05 (ROI 103.5), 2032 $6.50 (ROI 118.8), 2033 $7.54 (ROI 153.9), 2034 $10.22 (ROI 244.1), and 2035 $12.84 (ROI 332.2).
By 2040 the average price is $15.27 (ROI 414.1), and by 2050 it is $32.26 (ROI 986.2). Across these years, sentiment remains BULLISH from 2027 onward, indicating a strong long-term upside potential within the forecast. These are estimates, not guarantees, and actual results will vary with market conditions and outcomes.
Tap a question to reveal the answer.
2030 avg price $6.04; min $3.74; max $10.46; ROI 103.3%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with average price rising to $32.26 by 2050 and ROI reaching 986.2% by 2050; these are estimates, not guarantees.
Yes, forecast max reaches $10.46 in 2030; beyond that, 2033 max $14.34; 2034 max $19.92; 2035 max $25.61.
30-day range $2.02-$4.37; current price $2.97; RSI 40; SMA50 $3.42; SMA200 $3.65; support $2.80; resistance $5.34; sentiment NEUTRAL; annualized volatility 100%.
Market cap $195.59M; rank 3768.
Galectin Therapeutics Inc. Community Discussion
0Share your Galectin Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.